Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ0,00
KB0,00
PKN87,1287,151,03
Msft-0,32
Nokia4,1244,144-0,70
IBM1,37
Mercedes-Benz Group AG51,3851,4-1,12
PFE-0,45
19.07.2025 2:04:00
Indexy online
AD Index online
select
AD Index online
 

  • 18.07.2025
Anebulo Pharma Rg (NASDAQ Cons)
Závěr k 18.7.2025 Změna (%) Změna (USD) Objem obchodů (ks)
1,64 0,00 0,00 7 020
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 21.07.2025
Popis společnosti

Business Summary: Anebulo Pharmaceuticals, Inc. is a clinical-stage biotechnology company. It is engaged in developing treatments for cannabis toxicity, such as unintentional cannabis poisoning, acute cannabinoid intoxication (ACI) and the landscape of acute cannabis-induced conditions. Its lead product candidate is selonabant, a potent, small molecule antagonist of cannabinoid binding receptor type-1 (CB1), the primary receptor involved in the psychotropic effects of cannabinoids, with the potential to address the unmet medical need for a therapy to treat cannabis toxicity. Selonabant is orally bioavailable, rapidly absorbed, and has also been formulated for intravenous administration. Selonabant is intended to rapidly reverse the negative effects of cannabis-induced toxicity and reduce time to recovery. It is also prioritizing the advancement of a selonabant intravenous (IV) formulation as a potential treatment for pediatric patients with cannabis-induced CNS depression.
Financial Summary: BRIEF: For the six months ended 31 December 2024, Anebulo Pharmaceuticals Inc revenues was not reported. Net loss decreased 10% to $4.7M. Lower net loss reflects General and administrative - Balancing decrease of 38% to $883K (expense), Compensation and related benefits decrease of 34% to $731K (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$0.20 to -$0.17.



  • Poslední aktualizace: 01.01.0001
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
President, Chief Executive Officer, DirectorJonathan Mazelsky6423.10.2019
Executive Vice President, Chief Executive Officer, TreasurerAndrew Emerson4201.03.202501.03.2025
Chief Human Resources Officer, Executive Vice PresidentMichael Johnson48
Executive Vice President, General Counsel, Corporate SecretarySharon Underberg6331.12.202101.03.2019
Executive Vice President and General Manager, Point of Care Diagnostics and TelemedicineMichael Erickson51
Executive Vice President and General Manager, Global Reference Laboratories, Diagnostic Solutions and Information TechnologyMichael Lane5701.01.2025
Executive Vice President and General Manager, Veterinary Software and Services, Corporate Accounts and Customer ExperienceMichael Schreck57
Executive Vice President - Global CAG CommercialGeorge Fennell56
Executive Vice President - Global Strategy and CommercialTina Hunt5701.01.2025
Executive Vice President - Global Operations and R&DMartin Smith5701.01.2025